Our Investments
With a focus on developing and investing in Cannabis and Medical Fungi, we have completed two unique investments. The acquisition of Artizen Corporation represents our anchor platform from which we will expand in the global cannabis market. Taking a small stake in KRTL provides us with a unique position to develop Medical Fungi opportunities which will eventually lead to investment in or acquisition of a similar anchor platform for that segment.
01
The Artizen Brand
The Artizen brand is one of the original cannabis brands launched in Washington State in 2015. Offering premium quality flower and concentrates at affordable prices, Artizen branded products have generated over $200 million in retail valued sales. Its flagship strains retain their position in the top three most sold products
​
02
Zen Asset Management "ZAM"
ZAM is a diversified asset management company founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM provides services to several customers in Washington State, including four licensed cultivation facilities and one licensed processing facility.
​
03
KRTL Biotech
KRTL is a U.S. research and development company now working in Korea through KRTL Asia, with a consortium of experienced Korean and US doctors and researchers focused on Psilocybin research. The company’s scientists are leaders in cancer and neurology research, with over 80 years of experience in the research industry
​